The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11151 malaria professionals are enjoying the free benefits of MalariaWorld today

anti-malarial drug

Plasmodium falciparum histidine rich protein 2 (pfhrp2): an additional genetic marker suitable for anti-malarial drug efficacy trials

January 12, 2022 - 23:38 -- Open Access
Author(s): 
Wahib M. Atroosh, Yee-Ling Lau, Georges Snounou, Meram Azzani and Hesham M. Al-Mekhlafi
Reference: 
Malaria Journal 2022 21:2, 4 January 2022

Genotyping of the three Plasmodium falciparum polymorphic genes, msp1, msp2 and glurp, has been adopted as a standard strategy to distinguish recrudescence from new infection in drug efficacy clinical trials. However, the suitability of a particular gene is compromised in areas where its allelic variants distribution is significantly skewed, a phenomenon that might occur in isolated parasite populations or in areas of very low transmission. Moreover, observation of amplification bias has diminished the value of glurp as a marker.

NOT Open Access | Exploring potential of Plasmodium RUVBL proteins as anti-malarial drug target

December 14, 2021 - 20:51 -- NOT Open Access
Author(s): 
Khurana J, Shrivastava A, Singh A, Gupta A
Reference: 
J Biomol Struct Dyn. 2021 Dec 8:1-17

Although malaria related cases and deaths have consistently declined over time, growing resistance to existing anti-malarial drugs in Plasmodium remains a matter of extreme concern. Since we rely so heavily on use of chemotherapy for malaria treatment and knowing that all the available anti-malarial drug will become virtually useless in the near future, we have to increase our understanding of basic biology of the parasite as well as characterize new molecular targets that can be exploited for anti-malarial therapy. In the present study, PfRUVBLs (AAA family member proteins) were evaluated for their potential as novel anti-malarial drug target candidates, using computational approaches.

Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa

October 29, 2021 - 14:02 -- Open Access
Author(s): 
Christian Nsanzabana
Reference: 
Malaria Journal 2021 20:401, 13 October 2021

Artemisinin resistance has emerged and spread in the Greater Mekong Sub-region (GMS), followed by artemisinin-based combination therapy failure, due to both artemisinin and partner drug resistance. More worrying, artemisinin resistance has been recently reported and confirmed in Rwanda. Therefore, there is an urgent need to strengthen surveillance systems beyond the GMS to track the emergence or spread of artemisinin and partner drug resistance in other endemic settings. Currently, anti-malarial drug efficacy is monitored primarily through therapeutic efficacy studies (TES).

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

August 25, 2021 - 16:04 -- Open Access
Author(s): 
Xiong Y, Huang J
Reference: 
Chin Med. 2021 Aug 18;16(1):80

Artemisinin and its derivatives belong to a family of drugs approved for the treatment of malaria with known clinical safety and efficacy. In addition to its anti-malarial effect, artemisinin displays anti-viral, anti-inflammatory, and anti-cancer effects in vivo and in vitro. Recently, much attention has been paid to the therapeutic role of artemisinin in liver diseases.

Sub-national disparities in accessing anti-malarial drug treatment in eastern Indonesia

August 17, 2021 - 15:15 -- Open Access
Author(s): 
Ipa M, Laksono AD, Astuti EP, Prasetyowati H, Pradani FY, Hendri J, Ruliansyah A, Surendra H, Elyazar IRF
Reference: 
BMC Public Health. 2021 Aug 13;21(1):1548

Poor access to health care providers was among the contributing factors to less prompt and ineffective malaria treatment. This limitation could cause severe diseases in remote areas. This study examined the sub-national disparities and predictors in accessing anti-malarial drug treatment among adults in Eastern Indonesia.

NOT Open Access | Natural products for treatment of Plasmodium falciparum malaria: An integrated computational approach

July 7, 2021 - 15:03 -- NOT Open Access
Author(s): 
Muhseen ZT, Hameed AR, Al-Bhadly O, Ahmad S, Li G
Reference: 
Comput Biol Med. 2021 Jul;134:104415

Malaria is a life-threatening infectious disease with an estimated 229 million cases in the year 2019 worldwide. Plasmodium falciparum 1-deoxy-d-xylulose-5-phosphate reductoisomerase (PfDXR) is one of the key enzymes in the biosynthetic pathway of isoprenoid, (required for parasite growth and survival) and considered as an attractive target for designing anti-malarial drugs.

Balanced impacts of fitness and drug pressure on the evolution of PfMDR1 polymorphisms in Plasmodium falciparum

July 7, 2021 - 07:56 -- Open Access
Author(s): 
Marvin Duvalsaint, Melissa D. Conrad, Stephen Tukwasibwe, Patrick K. Tumwebaze, Jennifer Legac, Roland A. Cooper and Philip J. Rosenthal
Reference: 
Malaria Journal 2021 20:292, 30 June 2021

Anti-malarial drug resistance may be limited by decreased fitness in resistant parasites. Important contributors to resistance are mutations in the Plasmodium falciparum putative drug transporter PfMDR1.

SERCAP: is the perfect the enemy of the good

June 30, 2021 - 12:18 -- Open Access
Author(s): 
Nicholas J. White and François H. Nosten
Reference: 
Malaria Journal 2021 20:281, 24 June 2021

Single Encounter Radical Cure and Prophylaxis (SERCAP) describes an ideal anti-malarial drug that cures all malaria in a single dose. This target product profile has dominated anti-malarial drug discovery and development over the past decade.

Malaria epidemiology and anti-malarial drug efficacy in Guinea: a review of clinical and molecular studies

June 23, 2021 - 13:58 -- Open Access
Author(s): 
Mahamoud Sama Cherif, Prabin Dahal, Abdoul Habib Beavogui, Alexandre Delamou, Eugene Kaman Lama, Alioune Camara and Mamadou Pathe Diallo
Reference: 
Malaria Journal 2021 20:272, 16 June 2021

Malaria is one of the leading causes of mortality and morbidity in Guinea. The entire country is considered at risk of the disease. Transmission occurs all year round with peaks occurring from July through October with Plasmodium falciparum as the primary parasite species. Chloroquine (CQ) was the first-line drug against uncomplicated P. falciparum in Guinea until 2005, prior to the adoption of artemisinin-based combination therapy (ACT).

Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in four malaria endemic states of India

May 26, 2021 - 09:19 -- Open Access
Author(s): 
Sri Krishna, Sweta Mishra, Praveen K. Bharti, et al.
Reference: 
Malaria Journal 2021 20:229, 21 May 2021

Malaria is a major public health problem in India and accounts for about 88% of malaria burden in South-East Asia. India alone accounted for 2% of total malaria cases globally. Anti-malarial drug resistance is one of the major problems for malaria control and elimination programme. Artemether-lumefantrine (AL) is the first-line treatment of uncomplicated Plasmodium falciparum in north eastern states of India since 2013 after confirming the resistance against sulfadoxine-pyrimethamine. In the present study, therapeutic efficacy of artemether-lumefantrine and k13 polymorphism was assessed in uncomplicated P. falciparum malaria.

Pages

Subscribe to RSS - anti-malarial drug